Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
363 Results Found
Administration announces first Medicare drug negotiation list
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation Reduction Act designed to reduce health care costs.
Will Blue Shield’s New Pharma Model Disrupt the PBM Market?
A new plan will transition Blue Shield of California’s drug supply management from CVS Health’s PBM to five companies — a move the payer believes will save its 4.8 million members as much as $500 million a year in drug costs or about 10% to 15% of what it spends on drugs annually.
Drug prices weigh heavily on employers’ minds, according to new study
A new study by Business Group on Health reveals that, amid increases in the percentage of health care dollars spent on pharmacy, 92% of employers are concerned about high-cost drugs in the pipeline, with 91% reporting concern about pharmacy cost trends overall.
CMS revises initial guidance on Medicare drug price negotiation
The Centers for Medicare & Medicaid Services June 30 released revised guidance detailing how it will implement an Inflation Reduction Act program to negotiate Medicare prices with makers of certain high-cost, single-source drug and biological products in 2023 and 2024 for prices effective in 2026.
Flawed Report Aims to Deflect Attention From Role Insurer PBMs Play in High Drug Costs
A new AHIP “report” suggests that hospitals are significantly marking up the costs of drugs to the detriment of patients. They make baseless claims that specialty pharmacies, many of which insurers conveniently own through their pharmacy benefit manager (PBM) affiliates, provide a lower-cost alternative for patients.
Affordability Advocacy Agenda
Our shared focus with Congress and Administration is on providing relief from the pandemic, ensuring a smooth recovery, and rebuilding a better health care system for the future. The American Hospital Association continues to incorporate principles that promote improved affordability, value, and equity into our policy and advocacy activities.
Flawed Report Aims to Deflect Attention From Role Insurer PBMs Play in High Drug Costs
A new AHIP “report” suggests that hospitals are significantly marking up the costs of drugs to the detriment of patients. They make baseless claims that specialty pharmacies, many of which insurers conveniently own through their pharmacy benefit manager (PBM) affiliates, provide a lower-cost alternative for patients.
Analysis Gets it Wrong on Health Care Spending
A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation, “What drives health spending in the U.S. compared to other countries,” does not provide a full picture on health care spending in the U.S. while also downplaying the immense role that drug costs play in overall health care spending.
AHA blog: Flawed report aims to bury role of insurers in high drug costs
A new AHIP report makes baseless claims that hospitals drive up specialty drug costs when in fact insurance companies drive up profits by steering patients to their own specialty pharmacies, write AHA’s Mark Howell, director of policy and patient safety, and Bharath Krishnamurthy, director of health analytics and policy.
High & Rising Drug Prices: Myth vs. Fact
Get the facts on 8 common misconceptions about the rising costs of prescription drugs.